AMED stock icon

Amedisys
AMED

$97.17
0.02%

Market Cap: $3.18B

 

About: Amedisys Inc is a healthcare services company in the United States. The company brings healthcare to the home through the provision of home healthcare services, hospice services, high acuity care segment, and personal care services. The Home Health Segment provides skilled nurses, therapists, and aids to patients' homes throughout the United States, Hospice segment operates many centers designed to provide comfort and support for terminally ill patients, Personal Care Segment provides individuals with assistance in their daily living activities and High acuity care segment can deliver the essential elements of inpatient hospital, SNF care, and palliative care to patients in their homes. A majority of the company's revenue is derived from the Home Health segment.

Employees: 19,000

0
Funds holding %
of 6,686 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

20% more funds holding in top 10

Funds holding in top 10: 10 [Q1] → 12 (+2) [Q2]

14% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 35

2% more funds holding

Funds holding: 275 [Q1] → 280 (+5) [Q2]

0.72% less ownership

Funds ownership: 91.08% [Q1] → 90.36% (-0.72%) [Q2]

1% less capital invested

Capital invested by funds: $2.74B [Q1] → $2.71B (-$28.9M) [Q2]

12% less repeat investments, than reductions

Existing positions increased: 92 | Existing positions reduced: 104

85% less call options, than puts

Call options by funds: $14.2M | Put options by funds: $92.9M

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$101
4%
upside
Avg. target
$101
4%
upside
High target
$101
4%
upside

2 analyst ratings

positive
0%
neutral
100%
negative
0%
Deutsche Bank
Justin Bowers
83% 1-year accuracy
5 / 6 met price target
4%upside
$101
Hold
Downgraded
31 Jul 2024
Cantor Fitzgerald
Sarah James
67% 1-year accuracy
84 / 125 met price target
4%upside
$101
Neutral
Reiterated
25 Jul 2024

Financial journalist opinion